Loading
A woman whose pancreatic cancer carried a CTRC-NTRK1 fusion responded to larotrectinib for six months after chemotherapy failed, then developed resistance, showing both the promise and the limits of TRK inhibitors in this disease.
A 61-year-old with metastatic pancreatic ductal adenocarcinoma received gemcitabine, nab-paclitaxel and ADI-PEG 20 for 12 months (partial response), then modified FOLFIRINOX, before somatic profiling revealed a CTRC-NTRK1 fusion. Larotrectinib 100 mg twice daily gave a partial response at 2 months; progression at 6 months led to re-biopsy and the next-generation TRK inhibitor selitrectinib, then dabrafenib and trametinib for a BRAF V600E mutation; the patient died two months later.
NTRK fusions are under 0.5% of pancreatic cancers but carry a tumour-agnostic approval; this case is the published proof that the label applies here.
Shares NTRK1/2/3 gene fusion, Larotrectinib, NTRK, Pancreatic ductal adenocarcinoma.
Shares Eileen M. O'Reilly, KRAS wild-type pancreatic ductal adenocarcinoma, Tumour-agnostic (tissue-agnostic) approval, Pancreatic ductal adenocarcinoma.
Shares Eileen M. O'Reilly, Memorial Sloan Kettering Cancer Center, Pancreatic ductal adenocarcinoma.
Shares NTRK1/2/3 gene fusion, NTRK, Memorial Sloan Kettering Cancer Center.
Shares KRAS wild-type pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Eileen M. O'Reilly, Pancreatic ductal adenocarcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/